Načítá se...
Activation of AMPK sensitizes medulloblastoma to Vismodegib and overcomes Vismodegib‐resistance
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblastoma (MB) and other cancers. However, a significant proportion of these tumors fail to respond to Vismodegib after a period of treatment. Here, we find...
Uloženo v:
| Vydáno v: | FASEB Bioadv |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8171304/ https://ncbi.nlm.nih.gov/pubmed/34124601 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fba.2020-00032 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|